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a b s t r a c t
Osteoblast induction and differentiation in developing long bones is dynamically controlled by the
opposing action of transcriptional activators and repressors. In contrast to the long list of activators that
have been discovered over past decades, the network of repressors is not well-defined. Here we identify
the expression of Foxp1/2/4 proteins, comprised of Forkhead-box (Fox) transcription factors of the Foxp
subfamily, in both perichondrial skeletal progenitors and proliferating chondrocytes during endochon-
dral ossification. Mice carrying loss-of-function and gain-of-function Foxpmutations had gross defects in
appendicular skeleton formation. At the cellular level, over-expression of Foxp1/2/4 in chondroctyes
abrogated osteoblast formation and chondrocyte hypertrophy. Conversely, single or compound defi-
ciency of Foxp1/2/4 in skeletal progenitors or chondrocytes resulted in premature osteoblast differentia-
tion in the perichondrium, coupled with impaired proliferation, survival, and hypertrophy of
chondrocytes in the growth plate. Foxp1/2/4 and Runx2 proteins interacted in vitro and in vivo, and
Foxp1/2/4 repressed Runx2 transactivation function in heterologous cells. This study establishes Foxp1/
2/4 proteins as coordinators of osteogenesis and chondrocyte hypertrophy in developing long bones and
suggests that a novel transcriptional repressor network involving Foxp1/2/4 may regulate Runx2 during
endochondral ossification.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The axial and appendicular skeletons form through a process of
endochondral ossification. During this process, mesenchymal
progenitor cells within the cartilage anlage differentiate to chon-
drocytes. The chondrocytes then mature through resting, prolifer-
ating, and hypertrophic stages, and are finally replaced by invading
osteoblasts and blood vessels (Kronenberg, 2003). Meanwhile,
skeletal progenitor cells within the perichondrium are progres-
sively committed to an osteoblast lineage (Karsenty and Wagner,
2002; Long and Ornitz, 2013). The perichondrium is the major
reservoir of osteoblast precursors in developing long bones (Maes
et al., 2010), and osteoblast differentiation in the perichondrium is
tightly regulated by the progressive action of osteoblast-specific
transcription factors (Hartmann, 2009; Karsenty, 2008; Kobayashi
and Kronenberg, 2005; Kronenberg, 2003; Long, 2012).
An array of cofactors, such as Maf, Taz, Satb2, Gli2, Dlx5, Bapx1
and Msx2, promotes osteoblast differentiation by stimulating Runx2
expression or enhancing Runx2 activity (Long, 2012). Runx2 is an
early transcription factor that integrates multiple osteogenic signals
to induce mesenchymal progenitor cells toward osteogenic commit-
ment (Ducy et al., 1997; Komori et al., 1997; Otto et al., 1997). During
endochondral bone formation, some of these osteogenic signals
come from chondrocytes. For instance, Ihh secreted by prehyper-
trophic and hypertrophic chondrocytes promotes osteoblast differ-
entiation by activating Runx2. After Runx2 stimulates osteogenic
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commitment, Osterix and ATF4 sequentially enforce the differ-
entiation and maturation of these osteoblasts (Ducy et al., 1996;
Nakashima et al., 2002; Yang et al., 2004). Conversely, osteoblast
differentiation is suppressed by repressors such as Twist1, Hand2,
Zfp521, Schn3, Stat1, Tle, Hey, Hes and Hdac4, which perturb DNA
binding or nuclear translocation by Runx2, decrease Runx2 protein
expression, or degrade Runx2 protein (Javed et al., 2010; Long, 2012).
Loss of Runx2 activators or cofactors impairs bone formation or
homeostasis (Komori et al., 1997), and genetic inactivation of Runx2
repressors leads to enhanced osteoblast differentiation or ectopic
ossification. For instance, Hand2 null mice displayed enhanced
ossification in the branchial arch (Funato et al., 2009).
The Fox family of transcription factors, characterized by a
highly conserved forkhead DNA-binding domains, are essential
for regulating several developmental processes (Augello et al.,
2011; Eijkelenboom and Burgering, 2013; Katoh et al., 2013; Kume,
2011; Raychaudhuri and Park, 2011). For example, the Foxp1/2/3/4
subfamily regulates differentiation or proliferation of cardiomyo-
cytes (Wang et al., 2004; Zhang et al., 2010), B and T cells (Duhen
et al., 2012; Feng et al., 2009; Hu et al., 2006; Wang et al., 2014), ES
cells (Gabut et al., 2011) and various malignant cell-types (Chen
et al., 2011; Koon et al., 2007; Korac et al., 2009). This subfamily
regulates cell differentiation through transcriptional repressor
activity. Foxp1/2/4 proteins generally show overlapping expression
patterns in the lung, gut, and brain during development (Lu et al.,
2002; Shu et al., 2007; Takahashi et al., 2008), and in some cases,
these proteins are known to act cooperatively (Li et al., 2012,
2004). However, the role of Foxp1/2/4 genes in bone development
remains unclear. In this report, we employ genetic, histologi-
cal and molecular approaches to investigate the role of Foxp
genes during endochondral ossification. Our findings identify the




The Foxp1fl/fl (Feng et al., 2009), Foxp2fl/fl (French et al., 2007),
transgenic mice Prx1-Cre (Logan et al., 2002) and Col2-Cre mice (Lu
et al., 2013) have been described in previous studies. For transgenic
mice generation, Foxp1 (NM_053202.2) cDNA, Foxp2 (BC058960)
cDNA and Foxp4 (BC057110) cDNA were individually driven by
Col2a1 promoter and enhancer as previously reported (Yang et al.,
2003). The genotyping primers for the Col2-Foxp1, Col2-Foxp2, Col2-
Foxp4 and Foxp4fl/fl mice are provided in Supplementary material
Table S1. The genetic backgrounds of all knockout mice were
uniform mixtures of 129S1/SvIMJ and C57Bl/6J. All transgenic mice
were ICR background. All animal procedures were performed in
accordance with protocols set by Shanghai Jiao Tong University
(SYXK 2011-0112).
Generation of Foxp4 conditional knockout mice
Two Loxp sites were inserted into the Foxp4 gene at introns
9 and 14 (Supplementary material Fig. S4A). The targeted ES clones
were identified by PCR using primers P1/P2 and P3/P4 that generate
5473 bp and 4648 bp products, respectively (Supplementary mat-
erial Fig. S4B). The conditional allele of Foxp4fl is genotyped by
primers P5/P6 as a 290 bp fragment. Foxp4 was efficiently dele-
ted by Cre activity, as evidenced by the decreased levels of Foxp4
mRNA and protein in the E13.5 limbs from Prx1-Cre; Foxp4fl/fl mice
(Supplementary material Fig. S4D and E). Mice of homozygous
Foxp4fl/fl showed no obvious abnormality throughout life, suggest-
ing the Foxp4fl allele functions normally.
Skeletal preparation, histological, IHC analyses and lacZ staining
Paraffin and frozen sections of skeletal samples from the
transgenic and knockout mice at E15.5, E16.5 and E18.5 were
obtained and processed as previously reported (Guo et al., 2004).
Sections were stained as previously described using H&E for general
histology (Beyotime), von Kossa for analysis of mineralization, and
safranin O for analysis of proteoglycans (Guo et al., 2004). The
primary antibodies for IHC were the following: anti-Osterix (1:50,
Abcam, ab22552), anit-Runx2 (1:50, Santa Cruze, sc-10758), anit-
Collagen Type I (1:50, Millipore, AB765P), anti-Foxp1 (1:50, Milli-
pore, ABE68), anti-Foxp2 (1:200, Abcam, ab16046), anti-Foxp4
(1:50, Milipore, ABE74), anti-Patched (1:50, Santa Cruze, sc-6149),
anti-Ihh (1:50, Santa Cruze, sc-1196), anti-Flag (1:100, Agilent
Technologies, 200472), anti-His (1:100, GenScript, A00174), and
anti-BrdU (1:100, Abcam, ab6326). The secondary antibodies used
were the Alexa Fluor 488 conjugated (1:200, Invitrogen, A-21206)
and the Alexa Fluor 594 conjugated second antibody (1:200,
Invitrogen, A-11058 or A-11032). Mounting was performed with
DAPI fluorescent dye (Southern Biotech). Fluorescent microscopic
images were taken using a Leica SP5 confocal microscope. For LacZ
staining, the samples were at first performed by whole mount X-gal
staining as done previously (Day et al., 2005), and then re-fixed and
sectioned with 10 μm thick to observe the Cre enzyme activity.
In situ hybridization BrdU labeling and TUNEL assay
In situ hybridization for whole mount embryos or sections was
performed using digoxin-labeled probes as previously described
(Guo et al., 2009). Fragments of Foxp1 (NM_053202.2) cDNA, Foxp2
(BC058960) cDNA and Foxp4 (BC057110) cDNA were amplified by
PCR and subcloned into the pGEM-T vector to generate RNA probes,
respectively. All the oligos are provided in Supplementary material
Table S1. Other probes have been described previously: Sox9, Col2a1,
Col10a1, Mmp13, Opn, Ihh, Pthrp, Osx, Col1a1 (Akiyama et al., 2004;
Guo et al., 2004). For bromodeoxyuridine (BrdU) labeling, mice
received an intraperitoneal injection of BrdU (100 μg/g of body mass;
Sigma). Two hours later, mice were sacrificed and embedded in
paraffin for sectioning. TUNEL staining was performed using Dead-
End™ Fluorometric TUNEL System kit (Promega) according to the
manufacturer's instructions.
Luciferase reporter assay, cell culture and qRT-PCR
HEK-293T or Cos7 cells with a density of 0.5105 were plated in
24-well tissue and cultured until 90% confluent. Cells were trans-
fected according to manufacturer's instructions using using lipo-
fectamine™ 2000 (Invitrogen). Expression plasmids for p6OSE2-luc,
pOG2-luc, pOG2mOSE2-luc reporter constructs have been described
previously (Ducy and Karsenty, 1995). Cos7 cells were transfected
with p6OSE2-luc (0.08 μg) or pOG2mOSE2-luc (0.08 μg) reporter
plasmid together with the following expression plasmids as indi-
cated: Flag-Runx2 (0.24 μg), His-Foxp1, His-Foxp2, His-Foxp4, His-
Foxp1-N (0.48 μg), His-Foxp1-M (0.48 μg), His-Foxp1-N-M(0.48 μg)
and His-Foxp1-C (0.48 μg). Foxp1/2/4 dose-dependent transcrip-
tional repression of Runx2 was assayed using Foxp: Runx2 ratios of
1:3, 1:1, 2:1. HEK-293T cells were transfected with p6OSE2-luc
(0.16 μg) reporter plasmid together with the following expression
plasmids as indicated: Flag-Runx2 (0.16 μg), Flag-Runx2-Runt
(0.16 μg), His-Foxp1 (0.16 μg), His-Foxp2 (0.16 μg) and His-Foxp4
(0.16 μg). 4 ng pCMV-Renilla-luciferase plasmid (Promega) was
used for normalization. Empty pcDNA3.0 vector DNA was used to
equalize the total amount of DNA for all transfection assays.
Luciferase assays were performed 48 h after transfection by using
the Dual Luciferase Kit (Promega).
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The full-length cDNA of Foxp4 (BC057110) or EGFP (used as
control) was amplified by PCR and subcloned into the PMSCVpuro
retroviral vector. Retrovirus was generated by transfection of
PMSCVpuro-Foxp4 construct or PMSCVpuro-GFP construct into
Platinum-E Retroviral packaging cells using FuGENE 6 (Roche).
ATDC5 cells were cultured in a medium of DMED/F-12 supple-
mented with 5% FBS (Invitrogen). To induce chondrogenic diff-
erentiation of ATDC5 cells, the cells upon reaching confluence
were induced by differentiation medium by addition of insulin
(10 μg/ml, Sigma), human transferrin (10 μg/ml, Sigma), and
sodium selenite (10 μg/ml, Sigma). The ATDC5 cells overexpressing
Foxp4 or GFP protein were obtained by retroviral infection and
puromycin resistance selection. Similar overexpression was per-
formed in MC3T3 cells. MC3T3 cells were cultured in α-MEM
medium (Invitrogen) including 10% FBS. For osteogenic introduction,
the cells were cultured in the medium with addition of 10 mM
β-glycerolphosphate (Sigma), 50 μg/ml ascorbic acid (Sigma), and
10 nM dexamethasone (Sigma). Alcian blue staining for ATDC5 cells
was performed as previously report (Atsumi et al., 1990). For Alizarin
Red S staining, MC3T3 cells were fixed in 10% formalin for 30 min
and stained by 40 mM Alizarin Red S solution (pH 4.2) (Sigma).
RNA was extracted from cultured cells using the Trizol reagent
(Invitrogen) according to standard procedures. SuperScript™ III
First-Strand Synthesis System (Invitrogen) was used to reverse-
transcribe RNA. Real-time PCR was performed on ABI Prism 7500
Sequence Detection System (Applied Biosystems) using a FastStart
universial SYBR Green Master (ROX) kit (Roche). The samples
were normalized to actin expression. All primer sequences for
Foxp4 quantification could be found in Supplementary material
Table S1.
Plasmids
The epitope-tagged derivatives of full-length Foxp1 (NM_053
202.2), Foxp2 (BC058960), Foxp4 (BC057110) or Runx2 (NM_001
146038), containing carboxy-terminal His, carboxy-terminal Myc
or amino-terminal Flag tags as indicated were cloned in the
pcDNA3.0 vector (Invitrogen). The constructs encoding different
donmains of Runx2 (NT, Runt, RunxI, NT-Runt or Runt-RunxI) or
Foxp1 (N, M(LZ/ZF), C(FH), N-M(LZ/ZF)) as schematically drawn in
Figs. 7 and 8 were amplified by PCR, and products with amino-
terminal Flag tags or carboxy-terminal His tags respectively were
inserted into the pcDNA3.0 vector.
Co-IP/IP assay
Co-IP assays were performed by transfecting HEK-293T cells
with the indicated plasmids using lipofectamine™ 2000 (Invitro-
gen). After 48 h, cells were harvested. Cell extracts were subjec-
ted to immunoprecipitation with either the anti-Myc antibody
(1/2000, Roche, 11667149001), anti-His (1/2000, GenScript, A00174) or
anti-Flag (1/2000, Agilent Technologies, 200472) antibody as indica-
ted for overnight at 4 1C. The antibody was coupled to protein A/G
PLUS-Agrose (Santa Cruze, sc-2003). The immunoprecipitates were
washed eight times with washing buffer and analyzed by SDS-PAGE
and immunoblotting with antibody as indicated. For in vivo analysis,
Nuclear extracts from E13.5 limb were immunoprecipitated with
anti-Foxp1 antibody (Millipore, ABE68), anti-Foxp2 antibody (Abcam,
ab16046) or IgG (Santa Cruze, sc-2027), and then blotted with anti-
Foxp1 (1/1000, Millipore, ABE68), anti-Foxp2 (1/2000, Abcam, ab16046),
anti-Foxp4 antibody (1/1000, Milipore, ABE74) and anti-Runx2 antibody
(1/1000, Santa Cruze, sc-10758) as indicated.
Statistical analyses
Statistical analysis was performed by Student's t test using
GraphPad Prism 5 software. Data are represented as mean7SEM,
and significance was set at pr0.05. For BrdU labeling, at least
three individual samples analyzed and five to ten consecutive
sections from each sample were taken into account.
Results
Foxp1/2/4 genes are expressed in developing long bones
Expression patterns of the Foxp1/2/4 genes were examined in
the limb skeletons during endochondral ossification by in situ
hybridization and immunohistochemistry (IHC). At the E12.5 stage
of early skeletal primordial formation, in situ hybridization showed
redundant expression of Foxp1/2/4 in the digit ray of forelimbs as
well as hindlimbs, partially overlapping with expression of Sox9
and Gdf5 in the perichondrium and joint (Figs. 1A and S1A).
Similarly, in situ hybridization showed redundant expression of
Foxp1/2/4 in the perichondrium/periosteum of E13.5 digits and
E16.5 humerus (Fig. 1A and B). In IHC analysis of consecutive
sections of E16.5 distal humerus, the range of Foxp1/2/4 expres-
sion in the perichondrium was similar to Runx2, but differed from
that of the osteoblast marker Osx (arrows in Fig. 1C, a–e), implying
that Foxp1/2/4 may be active in the same cell types as Runx2.
Indeed, the Foxp1/2/4 proteins were mostly located in the nuclei
of perichondrial cells, partially overlapping with the Runx2 dis-
tribution (arrows in Fig. S1B). In addition to the expression of
Foxp1/2/4 in perichondrium, Foxp2 and Foxp4 were detected at
relatively lower levels in proliferating chondrocytes (Fig. 1C, b and
c). These results demonstrate that the murine Foxp1/2/4 genes are
redundantly expressed in the perichondrium and proliferating
chondrocytes of developing long bones.
Over-expression of Foxp1/2/4 in chondrocytes abrogates skeletal
ossification
To investigate the roles of Foxp1/2/4 in skeletogenesis, we
generated transgenic mice that overexpress Foxp1, Foxp2, and
Foxp4 transgenic mice in chondrocytes under the control of Col2a1
promoter and enhancer. We obtained two or three independent
founders for each transgenes. The severity of the ossification
defect varied between founders with the same transgene, possibly
due to the variances in copy number or ectopic expression levels of
the transgene. The founders with the most severe defects were
selected for further study. The over-expression of Foxp1/2/4 in the
chondrocytes of skeletons from each transgenic mouse was
validated by IHC with anti-Foxp1, anti-Foxp2 or anti-Foxp4 poly-
clonal antibodies (Fig. S2). The Col2-Foxp1, Col2-Foxp2 and Col2-
Foxp4 transgenic mice all showed perinatal lethality and smaller
size compared to wild-type controls (Fig. 2A). The transgenes
produced remarkable defects in endochondral ossification, as
indicated by decreased Alizarin red staining in skeletal prepara-
tions of forelimbs and hindlimbs of transgenic mice compared to
controls (Fig. 2A, b–b'' and c–c''). In contrast to the development of
long bones, Alizarin red staining in the skulls was impaired in a
relatively less extent in the transgenic embryos (Fig. 2A, d–d'').
Therefore, overexpression of Foxp1/2/4 in chondrocytes inhibits
endochondral ossification.
The expression of Col2a1 was relatively decreased in the
chondrocytes from Foxp transgenic skeletons (Fig. 2B, b–b''). In
addition, marked decreases of Col10a1 (hypertrophic chondrocyte
marker, B, c–c'' and Bg, Bg', B, i–i''), Opn (osteoblast marker, Fig. 2B,
e–e'' and k–k'') and Col1a1 (osteoblast marker, Fig. 2B, f–f'' and
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l–l'), safranin O (Fig. 2B, a–a'') and von Kossa (Fig. 2B, d–d'')
staining showed greatly reduced chondrocyte hypertrophy and
osteoblast differentiation in the growth plates of transgenic
embryos relative to wild-type controls. Consistent with these
findings, the expression of Ihh and Ptch1 was significantly abro-
gated in the Col2-Foxp2 transgenic embryos (Fig. S2D). Notably, the
Col2-Foxp1 and Col2-Foxp4 transgenic embryo appeared to retain
small mineralized domains in scapula whereas the Col2-Foxp2
mice had no mineralization at all (Fig. 2A, b'–b'').
To validate the suppressive role of Foxp genes in chondrocyte
hypertrophy and osteoblast differentiation, ATDC5 cells that are
capable of undergoing a chondrogenesis in vitro under induction
were transfected by Foxp4-expressing retrovirus. Compared to GFP-
expressing control retrovirus, the Foxp4-overexpressing cells showed
remarkably reduced mRNA expression of Col10a1, Runx2 by 14 days
post-transfection as well as lower levels of Ptch1 and Gli1 expression
by 21 days post-transfection (Fig. S3A–C). It displayed diminished
Alcian blue staining 21 days post-transfection (Fig. S3D). These
results are consistent with our in vivo results. In addition, over-
expression of Foxp4 in MC3T3 osteoblast precursor cells repressed
osteogenic differentiation, as evaluated by Alizarin red staining at 21
days post-transfection (Fig. S3E). Collectively, these findings suggest
that over-expression of Foxp1/2/4 in chondrocytes severely impairs
chondrocyte hypertrophy and osteoblast differentiation.
Foxp deficiency in perichondrium and chondrocytes perturbs skeletal
development
To further assess the role of Foxp1/2/4 in cartilage and bone
development, we used Col2-Cre to generate mice lacking Foxp in
the perichondrium and chondrocytes. Confirming that the Col2-
Cre mice we used have Cre activity in the perichondrium and
Fig. 1. Expression of Foxp1/2/4 in the limb during skeletal development. (A) Detection of Foxp1/2/4 expression by in situ hybridization in skeletal primordium at E12.5
(A, a–c) and E13.5 (A, a'–c'). Expression of Foxp1/2/4 is mainly observed in surrounding perichondrium. Expression of Sox9 and Gdf5 is also shown in (Ad–e) and (Ad'–e').
(B) Detection of Foxp1/2/4 expression in serial sections of the proximal tibia at E16.5. (Ba'), (Bb') and (Bc') show the enlargement of the boxed regions in (Ba), (Bb) and (Bc),
respectively. (C) IHC for Foxp1/2/4, Runx2 and Osterix (Osx) in serial sections of E16.5 distal humerus, counterstained with DAPI (blue). Arrows designate the onset of
expression of Foxp, Runx2 and Osx, respectively, in the E16.5 proximal humerus. Scale bar: 100 μm.
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chondrocytes, LacZ staining was evident in the perichondrium and
chondrocytes of Col2-Cre; R26R reporter mice (Fig. S5A). The Foxp1/
2/4 genes were targeted individually or in combination, and IHC or
western blot showed near-complete elimination of Foxp expression
in the intended tissue (Figs. S4D, E and S5B). However, growth of
heterozygous mice Col2-Cre; Foxp4fl/þ was significantly arrested at
2 weeks of age, precluding the generation of homozygous Col2-Cre;
Foxp4fl/flmutant mice. Therefore, Col2-Cre; Foxp4fl/þ mice were used
to assess the role of Foxp4 in long bone development. Not surpris-
ingly, the phenotype of single knockout mice was less severe than
the phenotype of the compound knockout mice. The single knock-
out mice survived postnatally for a long period up to 1 year. In
contrast, Foxp1/2 and Foxp1/4 compound knockout mice (Col2-Cre;
Foxp1/2fl/fl and Col2-Cre; Foxp1fl/fl; Foxp4fl/þ) died perinatally, pos-
sibly due to the severe skeletal dysgenesis described below.
To analyze skeletal deformities in Foxp mutant mice at E18.5 and
P10, overall skeletal preparations were analyzed with Alcian blue and
Alizarin red staining. At E18.5, the overall body size and the
appendicular skeleton were shortened in the single and compound
Foxp mutants compared to the wild-type controls (Fig. 3A). By P10,
the severity of attenuated skeletal growth increased as the genetic
dosage of Foxp1/2 decreased (Fig. 3C). Defective skeletal development
was not limited to the appendicular skeletons, as bone malforma-
tions were also detected in the skull. In the Col2-Cre; Foxp1/2fl/fl and
Col2-Cre; Foxp1fl/fl; Foxp4fl/þ compound mutants, both the cranium
and nasal defects included shortened nasal bones (double head
arrows) and disruption of basisphenoid bone development (yellow
arrows) of the cranial base in the compound mutants (Fig. 3B, a–f).
Together, these observations suggest that Foxp genes cooperatively
regulate skeletal development in a dose-dependent manner.
To identify the molecular changes associated with defective
skeletal development in the Foxp mutants, we performed histolo-
gical and IHC analyses in sections from E18.5 tibia of mutant
and control mice (Fig. 4). In the control tibia sections, von Kossa
staining showed initiation of mineralization in the perichondrium/
periosteum cells neighboring hypertrophic chondrocytes (outlined
in Fig. 4A, A'). In contrast, in the compound Foxp mutant mice,
we observed precocious mineralization extending to perichond-
rial cells neighboring the proliferating chondrocytes (marked by
arrows in Fig. 4D, D' and E, E'). This effect was observed, but much
more subtle in the single mutant.
In agreement with these results, osteoblast differentiation in the
perichondrium was advanced in the compound mutant mice com-
pared to the control, as indicated by the elevated expression of
osteoblast markers Osx (Figs. 4I, J and 5A, g–h), ColI (Figs. 4N, O, 5
Ak–l) and Opn (Fig. 4S and T). These findings demonstrate advanced
osteoblast differentiation, maturation and mineralization during endo-
chondral ossification in Foxp-deficient mice. Therefore, we hypothe-
sized that that the Foxp genes may regulate osteogenic commitment.
Foxp deficiency in skeletal progenitor cells leads to precocious
osteogenic commitment
To explore the effect of Foxp deficiency on osteogenic commit-
ment of skeletal progenitor cells, we used Prx1-Cre to eliminate
Foxp in the mesenchymal progenitor cells (Logan et al., 2002). Like
the Col2-Cre knockout mice, which lack Foxp in the perichondrium
and chondrocytes, the Prx1-Cre; Foxp1/2fl/fl compound knockout
mice had osteogenic defects. Compound knockout of Foxp alleles
with either Prx1-Cre or Col2-Cre resulted in relatively advanced
expression of Runx2 and Osx in the perichondrium of E15.5
humerus sections (arrows in Fig. 5A, a–h and a'–h'), suggesting
that Foxp deficiency stimulates early osteogenic induction and
commitment. Moreover, ColI expression was elevated in the
perichondrium adjacent to proliferating chondrocytes osteoblast
maturation in the compound Foxp mutant, indicative of advanced
osteoblast maturation (arrows in Fig. 5A, i–l and i'–l'). These
results suggest that Foxp deficiency in the mesenchymal progeni-
tor cells leads to a premature osteogenic commitment.
Next we tested whether Foxp deficiency affected osteoblast
proliferation in addition to osteogenic commitment. To assess
osteoblast proliferation in vivo, E15.5 animals were treated with
BrdU, and two hours later, BrdU was quantified in the proximal
humerus. IHC analyses showed that a greater percentage of
osteoblast defined by Osx-expressing cells, were BrdU positive in
the Prx1-Cre; Foxp1/2fl/fl mutants as compared to the Foxp1/2fl/fl
controls (Fig. 5Bm', Bn' and C). In addition, the Osx-expressing cell
layers were expanded in the perichondrium of compound mutant
Fig. 2. Abrogated chondrocyte hypertrophy and endochondral ossification in the Foxp1/2/4 transgenic mice. (A) Skeletal preparations from wild-type and Col2-Foxp1/2/4
transgenic mice. Bone is stained by Alizarin red, whereas cartilage is stained by Alcian blue. Skeletons of the Col2-Foxp1 (Aa–d) and Col2-Foxp2 (Aa'–d') mice were examined
at E18.5, whereas skeletons of the Col2-Foxp4 (A, a''–d) mice were analyzed at P0. Lateral views of whole skeletons are shown in (Aa), (Aa') and (Aa''); forelimbs are shown in
(Ab), (Ab') and (Ab''); hindlimbs are shown in (Ac), (Ac') and (Ac''); dorsal view of skulls are shown in (Ad), (Ad') and (Ad'). (B) Indicated markers of bone development were
detected by in situ hybridization in serial sections of the E18.5 humeri from the Col2-Foxp1/2 transgenic mice and in the P0 tibia from the Col2-Foxp4 transgenic mice.
Safranin O staining and von Kossa staining are also shown in (Ba, Ba', Ba'', Bg, Bg') and (Bd, Bd', Bd',Bj, Bj'). The Col10a1-positive structure in Fig. 2Bc'' should be the scapula.
The van Kossa positive structure in 2Bd' is the clavicle. Scale bar: 200 μm.
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mice compared to controls (brackets in Fig. 5Bm', Bn' and C). These
results suggest that Foxp deficiency in mesenchymal progenitor
cells led to enhanced osteoblast proliferation. Collectively, these
results support the hypothesis that Foxp genes are important for
regulating osteogenic commitment, osteoblast proliferation and
differentiation during endochondral ossification.
Foxp deficiency in the perichondrium and chondrocytes impairs
chondrogenesis
In addition to regulating osteogenic commitment and dev-
elopment, the Foxp genes could affect skeletal development by
regulating chondrogensis. To investigate this possibility, we per-
formed histological analyses and in situ hybridization on E18.5
sections from the Col2-Cre; Foxp mutants and controls. Safranin O
staining (brackets in Fig. 6A'–E') and Col10a1 expression (brackets
in Fig. 6F–J) were used to detect collagen II and hypertrophic
chondrocytes, respectively, these analyses showed smaller dom-
ains of hypertrophic chondrocytes in the growth plates of E18.5
tibia from the single and compound mutant mice compared to
controls. Confirming these results, the tibia of E15.5 mutants
showed a shorter distance between the two Col10a1-expressing
domains and shorter Opn- and Mmp13-expressing domains (dou-
ble head arrows in Fig. S7A), indicative of decreased chondrocyte
Fig. 3. Compound deficiency of Foxp1/2/4 impairs skeletal growth. (A) Alizarin red/Alcian blue staining of skeletons isolated from the E18.5 Col2-Cre; Foxp1fl/fl, Col2-Cre;
Foxp2fl/fl, Col2-Cre; Foxp1/2fl/fl, Col2-Cre; Foxp1fl/fl; Foxp4fl/þ embryos, including the whole skeleton (Aa–e), forelimb (Af–j), hindlimb (Ak–o). (B) Magnified view of E18.5 heads
(Ba–f) in the Col2-Cre; Foxp1/2fl/fl and Col2-Cre; Foxp1fl/fl; Foxp4fl/þ mice, showing craniofacial malformations and shortening of the nasal bones. The formation of the cranial
base bones (Bd–f, yellow arrows) is impaired in the mutants with respect to the controls. Bs, basisphenoid; bo, basioccipital; ps, presphenoid. (C) Skeletal preparations of the
P10 Col2-Cre; Foxp1fl/þ , Col2-Cre; Foxp1fl/þ; Foxp2fl/þ , Col2-Cre; Foxp1fl/þ ; Foxp2fl/fl, Col2-Cre; Foxp1fl/fl; Foxp2fl/þ mice (littermates). Bone is stained with Alizarin red, where as
cartilage is stained with Alcian blue.
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hypertrophy. In contrast, the Col2-Cre; Foxp1/2fl/fl mutant showed
an increase in proliferating or prehypertrophic chondrocytes
compared to the control, assessed by expression of Ihh and Pthc1
(arrows in Fig. S7B). Therefore, Foxp deficiency may delay
chondrocyte hypertrophy and maturation during endochondral
ossification.
Next, to assess whether decreased proliferation or increased
apoptosis might contribute to the reduction in hypertrophic
chondrocytes, we performed the BrdU assay described above and
TUNEL analysis in the proximal tibia of E18.5 mutants and the
Col2-Cre control. Compared to the control, BrdU levels were
significantly reduced in proliferating zones of all Foxp single and
compound mutants and in the resting zones of all mutants except
the Foxp1 single mutant (Fig. 6K–O, U and V). TUNEL analysis
showed significantly increased chondrocyte apoptosis in all the
Foxp mutant mice except the Foxp1 single mutant (Fig. 6P–T, W).
Together, these data indicate that depletion of Foxp genes affects
chondrocyte proliferation, survival and hypertrophy.
Foxp1/2/4 proteins inhibit the transacriptional activity of Runx2
The defects in endochondral ossification observed in Foxp
deficient mice were opposite to previously described in Runx2 /
mice (Komori et al., 1997; Takarada et al., 2013). Given the over-
lapping expression patterns of Foxp and Runx2, we suspected that
Foxp1/2/4 may influence osteogenic differentiation and chondro-
cyte hypertrophy by regulating Runx2. To address this possibility,
we first examined the impact of Foxp proteins on Runx2 transac-
tivation via reporter assays employing luciferase constructs
(pOG2-Luc or p6OSE2-Luc) driven by consensus Runx2 binding
sites in their promoters (Ducy and Karsenty, 1995). COS7 cells were
transfected with the p6OSE2-Luc reporter and with Runx2 and
Foxp expression vectors as indicated. As expected, co-transfection
of p6OSE2-Luc and the Runx2 expression vector induced luciferase
activity. Co-transfection of p6OSE2-Luc with Runx2 and Foxp1,
Foxp2 or Foxp4 significantly suppressed luciferase activity, with
the extent of suppression dependent on the dose of Foxp1, Foxp2
Fig. 4. Deletion of Foxp1/2/4 by Col2-Cre advanced mineralization and osteoblast differentiation in the perichondrium. (A–E') Von Kossa staining of the equivalent sections of
E18.5 tibiae (A–E); boxed regions are magnified in (A'–E'). (F–T) Expression of osteoblast markers Osx (F–J) and ColI (K–O) were detected by IHC, and Opn (P–T) was examined
by in situ hybridization. The dashed lines delineate the proliferative/hypertrophic zone. P, proliferative zone; H, hypertrophic zone. Scale bar: 100 μm.
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or Foxp4 (Fig. 7A). Interestingly, co-expressing various combina-
tions of Foxp1/2/4 did not further suppress Runx2 transactivation
activity beyond the suppression caused by single Foxp proteins at
the same total dose (Fig. 7B). To confirm that Foxp proteins
specifically suppressed Runx2-induced luciferase activity, we
repeated the assay using the pOG2mOSE2-Luc reporter, in which
the Runx2 binding sites are mutated. As expected, neither Runx2
nor the Foxp proteins significantly changed the luciferase activity
of this construct. These results demonstrate that Foxp proteins can
suppress Runx2 transactivation activity, suggesting that Foxp
complexes may function as a negative regulator of Runx2 in
osteoblast lineages.
Runt is the DNA binding domain of Runx2 protein and the Runt
domain alone induced luciferase activity at levels comparable to full-
length Runx2 protein. Interestingly, various Foxp proteins suppressed
luciferase induction by the Runt domain (Fig. 7D), suggesting that
these proteins may directly bind the Runt domain of Runx2. Foxp
proteins contain forkhead, leucine-zipper and zinc-finger domains,
which are responsible for DNA-binding and homotypic or hetero-
typic proteins interactions, respectively (Wang et al., 2003). To
determine which domain(s) are involved in Runx2 suppression, we
created construct for expressing the Foxp1 N-terminal domain,
middle domain (M, containing the leucine zipper and zinc finger
domain), or C-terminal domain (containing the forkhead domain)
independently or the N-terminal and middle domains together. In
the luciferase assay with full-length Runx2, each domain of Foxp1
suppressed Runx2 transactivation (Fig. 7E), although no single
domain suppressed Runx2 activity as effectively as the full-length
protein. Collectively, these findings suggest that Foxp complexes may
downregulate Runx2 activity during endochondral ossification by
interacting with the Runt domain.
The Foxp1/2/4 complex interacts with Runx2
To directly test whether Foxp1/2/4 proteins can interact with
Runx2, we performed co-immunoprecipitation experiments on
extracts from 293T cells cotransfected with Flag-tagged Runx2 and
His- or Myc-tagged Foxp constructs. As shown in Fig. 8A–C, Runx2
protein was efficiently co-immunoprecipitated with each Foxp
protein. In addition, IHC with anti-Flag and anti-His antibodies
showed colocalization of Flag-tagged Runx2 and His-tagged Foxp1,
2, or 4 in the nuclei of cotransfected Cos7 cells (Fig. S8). Consis-
tent with these in vitro results, endogenous Foxp1 was efficiently
co-immunoprecipitated with Foxp2, Foxp4 and Runx2 in nuc-
lear extracts from E13.5 limbs (Fig. 8D and E). These analyses
Fig. 5. Loss of Foxp1/2/4 leads to precocious osteogenic commitment from mesenchymal progenitor cells. (A) IHC analysis of Runx2, Osx and ColI expression in equivalent
sections of E15.5 humeri from the Foxp1/2fl/fl (Aa, Ae, Ai), Prx1-Cre; Foxp1/2fl/fl (Ab, Af, Aj), Col2-Cre; Foxp1/2fl/fl (Ac, Ag, Ak) and Col2-Cre; Foxp1fl/fl; Foxp4fl/þ (Ad, Ah, Al)
embryos. The boxed regions in (Aa–d, i–l) are enlarged in (Aa'–d', i'–l'). Dashed lines delineate the proliferative/hypertrophic zone. (B) Double staining of BrdU (red) and Osx
(green) in the equivalent sections of E15.5 humeri from Foxp1fl/þ; Foxp2fl/þ (Bm) and Prx1-Cre; Foxp1/2fl/fl (Bn) embryos, counterstained with DAPI (blue). (Bm') and (Bn') are
high-magnification images of the boxed regions in (Bm) and (Bn), respectively. (C) Quantitative analysis indicates that the width of Osx-positive domains and the percentage
of Osx-positive cells over perichondrial DAPI-positive cells are increased in the mutant (n¼3). Brackets indicate the width of Osx expression regions in the perichondrium. P,
proliferative zone; H, hypertrophic zone. Scale bar: 100 μm.
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demonstrate that Foxp1/2/4 proteins interact with Runx2 in vivo
and in vitro.
To identify the domains involved in the interaction between
Foxp1/2 and Runx2, truncated forms of Runx2 were cotransfected
into Cos7 cells with Flag-tagged Runx2, and interactions were
assessed by co-immunoprecipitation and His-tagged Foxp1/2/4
vectors (Fig. 8G). All forms of Runx2 that included the Runt domain
interacted with Foxp2, while forms of Runx2 that lacked the Runt
domain did not interact with Foxp2 (Fig. S9). Next, we used co-
immunoprecipitation to test whether the Foxp1 C-terminal domain,
which contains the forkhead domain, was sufficient for interac-
tions with full-length Runx2. Indeed, the Foxp1 C-terminal domain
was co-immunoprecipitated with Runx2 (Fig. 8F). Taken together,
these results imply that Foxp1/2/4 bind to Runx2 via interactions
between the Runx2 Runt domain and the C-terminal domain of
Foxp proteins.
Fig. 6. Ablation of Foxp1/2/4 impairs chondrocyte hypertrophy. (A–E) Safrain O staining of equivalent sections in E18.5 tibiae isolated from the various Col2-Cre; Foxpmutant
mice. P, proliferative zone; H, hypertrophic zone. (A'–E') Magnification of the boxed region in (A–E). (F–J) Detection of Col0a1 expression by in situ hybridization validates the
shortened hypertrophic domains of the mutant tibiae. (K–O) IHC for BrdU in the sections from E18.5 proximal tibiae as detected by anti-BrdU staining. RZ: the resting zone;
PZ: proliferating zone; PreH: prehypertrophic zone. (P–T) Apoptosis as detected by TUNEL assay in the sections from E18.5 proximal tibiae. RZ. (U–V) The proliferating
indexes which mean the rate of BrdU-positive chondrocytes in all resting or proliferating chondrocytes in (K–O) were shown in (U) and (V), respectively. (W) Apoptosis
percentage showing the rate of TUNEL-positive cells in all nonhypertrophic chondrocytes in (P–T). nZ3. ns: nonsense, (n) po0.05, (nn) po0.01, (nnn) po0.001. Scale bar:
100 μm.
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Discussion
In this study, we investigated the role of Foxp genes during
endochondral ossification by generating transgenic mice with
gain-of-function and loss-of-function Foxp mutations. Overexpres-
sion of individual Foxp1/2/4 genes disrupted osteoblast differen-
tiation and chondrocyte hypertrophy, while single or combined
deficiency of Foxp1/2/4 led to precocious ossification and defective
chondrogenesis in the growth plates. Thus, the Foxp1/2/4 proteins
are important for proper long bone development. Substantiating
this conclusion, we found that Foxp1/2/4 expression in the peri-
chondrium and proliferating chondrocytes of appendicular skele-
tons overlaps with expression of Runx2, a central regulator of end-
ochondral ossification. Moreover, Foxp1/2/4 physically interacts
with Runx2 and inhibits the transactivation function of Runx2.
Collectively, these results implicate a novel pathway for the regula-
tion of endochondral ossification.
We propose that Foxp1/2/4 proteins coordinate osteogenesis
and chondrogenesis during long bone development by regulating
Runx2 (Fig. 8K). This is a central factor in regulating bone
development, as several repressors or corepressors, including
Twist1/2, Zfp521 and Hdac4, have been reported to modulate
osteoblast differentiation and chondrocyte hypertrophy through
their differential interaction with Runx2 protein (Bialek et al.,
2004; Correa et al., 2010; Hesse et al., 2010; Shimizu et al., 2010;
Vega et al., 2004). Runx2 regulates osteoblast differentiation and
chondrocyte hypertrophy partially through the induction of Ihh
expression (Yoshida et al., 2004), and we detected altered Ihh
Fig. 7. Foxp1/2/4 inhibits the transcriptional activity of Runx2. (A) Transactivation by Runx2 was measured using a luciferase assay in Cos7 cells cotransfected with p6OSE2-
Luc reporter (0.08 μg), Runx2 (0.24 μg) and increasing doses of Foxp1/2/4 expression constructs (at Foxp/Runx2 ratios: 1:3; 1:1; 2:1). (B) The effects of varying combinations
of Foxp1/2/4 on Runx2-induced transactivation were assessed using a luciferase assay with the pOG2-Luc reporter in Cos7 cells, as described in A. (C) As a control, the
luciferase assay was repeated in Cos7 cells using the pOG2mOSE2-Luc reporter, in which the Runx2 binding site required for Runx2 transactivation is mutated. (D) Transient
cotransfection of the p6OSE2-Luc reporter with expression vectors for Runt domain, Runx2 and Foxp1/2/4 in HEK-293T cells. (E) Top panel: regions of Foxp1. N, N-terminus
containing the poly(Q) region; M, middle, including the leucine zipper/zinc finger (LZ/ZF); and C, the C-terminal portion of Foxp1 employed for the transfections. Bottom
panel: full-length or truncated forms of Foxp1 were transiently expressed in COS7 cells co-transfected with the p6OSE2-Luc reporter and Runx2, and Runx2-induced
transactivation was analyzed as above. Data are shown as mean7SEM, and n¼3. Significance was determined by t-test. (n) Po0.05, Foxp samples versus control. (#)
Po0.05, Foxp samples versus Runx2 or Runt.
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signaling in the Foxp gain-of-function and loss-of-function mutants.
Thus, dysregulated Runx2-induced Ihh signaling may account for the
impaired osteoblast differentiation and chondrocyte hypertrophy in
Foxp mutant mice.
Interestingly, Foxp deficiency in skeletal progenitor cells was
associated with changes in Runx2 expression and cellular mor-
phology in proliferating chondrocytes. Some proliferating chon-
drocytes in the Foxp mutants appeared to retain characteristics of
prehypertrophic chondrocytes, with somewhat larger size and less
organized arrangement compared to controls. In addition, expres-
sion of Runx2 and Osx was slightly elevated in perichondrium
adjacent to resting or proliferating chondrocytes. Given that
elevated Runx2 expression in the perichondrium has been shown
to inhibit chondrocyte proliferation and hypertrophy (Hinoi et al.,
2006), the gross defects in bone development in the Foxp mutants
may result from combined regulation of Runx2 activity in the
perichondrium and proliferating chondrocytes. However, it is
important to note that the Foxp proteins may coordinate osteo-
genesis and chondrogenesis via multiple pathways, including
pathways that are independent of Runx2. For example, Foxo
proteins have been reported to regulate osteoblast proliferation
and differentiation through interactions with Runx2, CREB and
ATF4 (Almeida, 2011; Kode et al., 2012).
Furthermore, although our data support shared roles for Foxp1/
2/4 proteins in regulating endochondral ossification via Runx2,
there are important differences in the expression patterns and
contributions of individual Foxp1/2/4 proteins during bone devel-
opment. These differences suggest that the individual Foxp1/2/4
proteins play overlapping yet distinct roles in regulating osteo-
genic targets. For example, the overlapping expression patterns of
Fig. 8. Foxp1/2/4 physically interacts with Runx2. (A–C) In vitro interactions between Foxp1/2/4 and Runx2 were assessed by co-immunoprecipitation in HEK-293T cells
cotransfected with the indicated vector combinations of His-Foxp1/Flag-Runx2 (A), His-Foxp2/Flag-Runx2 (B) or Myc-Foxp4/Flag-Runx2 (C). Cell lysates were prepared and
co-immunoprecipitated with anti-Flag or anti-His and then blotted with anti-His, anti-Flag or anti-Myc. (D, E) To assess in vivo interactions of endogenous Foxp and Runx2,
nuclear extracts prepared from E13.5 limbs were immunoprecipitated with anti-Foxp2 or IgG and blotted with anti-Foxp2, anit-Foxp4 or anti-Runx2 antibody (D), or
immunoprecipitated with anti-Foxp1 antibody and blotted with anti-Foxp1, anti-Foxp2, anti-Foxp4 or anti-Runx2 antibody (E). (F) Runx2 co-immunoprecipitates with the
C-terminal of Foxp1 containing forkhead (FH) domain (Foxp1-C). 293T cells were cotransfected with Flag-tagged Runx2 and the His-tagged Foxp1-C fragment, which
included the forkhead domain (FH). Co-immunoprecipitation was performed as indicated. (G) Proposed mechanism by which the Foxp complex regulates osteogenesis and
chondrocyte hypertrophy of the growth plate: Foxp1/2/4 complex regulates osteoblast differentiation and chondrocyte hypertrophy partially through inhibiting Runx2
activity.
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Foxp1/2/4, Sox9 and Gdf5 in early digit rays indicated that Foxp
genes are induced early in perichondrial skeletal progenitor cells.
However, Foxp4 was preferentially expressed in the distal digit at
E12.5 and E13.5, while Foxp1 expression was relatively enriched in
the perichondrium of the second phalange. Foxp2 showed mod-
erate expression in the perichondrium of all digits. In terms of
function, deletion of a single allele of Foxp4 by Col2-Cre severely
arrested skeletal growth and led to osteogenic defects as severe as
those caused by the dual, homozygous deletion of Foxp2 and
Foxp1. Yet in some cases, deletion of Foxp2 and/or Foxp1 had a
greater effect than deletion of Foxp4; for example, the ectopic
activation of Ihh signaling in resting/proliferating chondrocytes
was more remarkable in the Col2-Cre; Foxp1/2fl/fl mutant than in
the Col2-Cre; Foxp1fl/fl; Foxp4fl/þ mutant (Fig. S7B). In addition,
Foxp2 deficiency caused the most severe defects in chondrocyte
proliferation while Foxp1/4 deficiency had the greatest impact on
chondrocyte apoptosis. Thus, although the Foxp1/2/4 proteins
have significant redundancy and may regulate common sets of
target genes as a trimeric complex, it is likely that they also play
differential roles in the regulation of osteoblast differentiation and
chondrogenesis, perhaps through various combinations of homo-
or hetero-dimers.
If distinct Foxp complexes have different roles in osteoblast
differentiation and chondrogenesis, it follows that the Foxp genes
should have context- and time-dependent functions in bone devel-
opment. Indeed, while osteogenic differentiation was advanced in
the long bones of the E15.5 Prx1-Cre; Foxp1/2fl/fl mutant, ossification
was retarded in the parietal skull bone (Fig. S6). Thus, Foxp proteins
appear to context-dependent roles in endochondral and intramem-
branous ossification. Thus, Foxp proteins appear to play a complex
series of regulatory roles in bone development, and these roles may
vary with different protein complexes, developmental stages, and
tissue contexts. Additional studies will be required to fully delineate
these regulatory mechanisms. In conclusion, our study suggests that
Foxp1/2/4 proteins regulate endochondral ossification through their
interaction with Runx2 and suppression of Runx2 activity. The study
of Foxp1/2/4 provides a new transcriptional repressor that differen-
tially controls osteoblast differentiation and chondrocyte hypertro-
phy during long bone development.
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